Brokerages Set Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Target Price at $6.75

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) have received an average rating of “Hold” from the nine analysts that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $6.75.

ZNTL has been the subject of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Zentalis Pharmaceuticals in a research note on Friday, May 22nd. Wall Street Zen cut shares of Zentalis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, August 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research note on Monday, July 6th. Rodman & Renshaw initiated coverage on shares of Zentalis Pharmaceuticals in a research note on Thursday, July 23rd. They issued a “buy” rating and a $11.00 target price for the company. Finally, Mizuho began coverage on shares of Zentalis Pharmaceuticals in a report on Friday, July 17th. They issued an “outperform” rating and a $8.00 target price on the stock.

Insider Activity at Zentalis Pharmaceuticals

In other news, major shareholder Group Walters acquired 4,335,000 shares of the stock in a transaction that occurred on Friday, August 14th. The stock was acquired at an average price of $3.50 per share, for a total transaction of $15,172,500.00. Following the transaction, the insider directly owned 17,844,973 shares in the company, valued at approximately $62,457,405.50. This represents a 32.09% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. 3.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. CTC Alternative Strategies Ltd. acquired a new position in shares of Zentalis Pharmaceuticals in the 1st quarter valued at approximately $29,000. Spark Investment Management LLC bought a new position in Zentalis Pharmaceuticals in the second quarter valued at approximately $61,000. The Manufacturers Life Insurance Company bought a new position in Zentalis Pharmaceuticals in the second quarter valued at approximately $69,000. Barr E S & Co. boosted its holdings in shares of Zentalis Pharmaceuticals by 43.8% in the fourth quarter. Barr E S & Co. now owns 57,500 shares of the company’s stock valued at $78,000 after buying an additional 17,500 shares during the period. Finally, State of Wyoming bought a new stake in shares of Zentalis Pharmaceuticals during the second quarter worth $91,000.

Zentalis Pharmaceuticals Stock Down 0.3%

ZNTL stock opened at $3.50 on Thursday. Zentalis Pharmaceuticals has a twelve month low of $1.21 and a twelve month high of $6.95. The company has a market cap of $250.85 million, a P/E ratio of -1.79 and a beta of 1.85. The business’s fifty day moving average is $4.27 and its 200-day moving average is $3.83.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.10). Research analysts anticipate that Zentalis Pharmaceuticals will post -2.14 earnings per share for the current fiscal year.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc (NASDAQ: ZNTL) is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company’s research programs are designed to address biological mechanisms involved in tumor growth, resistance to treatment and disease progression.

Zentalis’ lead product candidate is azenosertib, formerly known as ZN-c3, an oral, selective WEE1 kinase inhibitor. The company is evaluating azenosertib in clinical studies involving solid tumors and hematologic malignancies, including ovarian cancer, uterine serous carcinoma and other cancers.